Sale of QVQ Holdings BV shares -- 121 -------------------------------------------- ------ ------ Net cash used in investing activities (328) (509) -------------------------------------------- ------ ------ Financing activities: Proceeds on share issuance, net of transaction costs 1,507 -- Repayment of leases (801) (715) Proceeds on debenture issuance, net of transaction costs 4,059 -- ---------------------------------------- ------ ------ Net cash provided by (used in) financing activities 4,765 (715) -------------------------------------------- ------ ------ Increase (decrease) in cash during the period 370 (1,794) Foreign exchange (294) (468) Cash -- beginning of the period 3,545 8,366 -------------------------------------------- ------ ------ Cash -- end of the period 3,621 6,104 -------------------------------------------- ------ ------ Cash is comprised of: Cash 3,534 6,017 Restricted cash 87 87 -------------------------------------------- ------ ------ 3,621 6,104 ---------------------------------------- ------ ------ Cash paid for interest -- -- Cash paid for income tax -- -- -------------------------------------------- ------ ------
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/
CONTACT:
Investor Relations Contact
investors@ipatherapeutics.com
(END) Dow Jones Newswires
December 10, 2024 08:30 ET (13:30 GMT)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。